For example, midostaurin is added to target FLT3-ITD/TKD mutations; gemtuzumab ozogamicin (GO) is added to target the high expression of CD33; and CPX351 is added to target AML with myelodysplasia-related changes (AML-MRC). The gene discussed is FLT3; the disease is acute myeloid leukemia.